Medication Management

Lurasidone, an oral atypical antipsychotic, is a first-line treatment option for the management of schizophrenia in adults and adolescents.

Christine Baeder, senior vice president and chief operating officer for U.S. generics, Teva Pharmaceuticals USA is the 2023 AAM chair of the board.

Generic Latuda is used to treat a depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients as monotherapy.

Amgen's Amjevita is the first U.S. biosimilar to AbbVie's Humira.

Important personnel changes you should know this week about the Association for Accessible Medicines, Maesa and more.

An aging population combined with increasing numbers of people diagnosed with chronic diseases are among the top factors set to influence innovation in the generics drug market in 2023.

Momentum appears to be growing around several legislative and regulatory issues that are important to retail pharmacy, including PBM reform at both the state and federal levels.

Orserdu (elacestrant) is the first and only treatment specifically indicated for patients with ESR1 Mutations in ER+, HER2- advanced or metastatic breast cancer.